<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04819893</url>
  </required_header>
  <id_info>
    <org_study_id>CREUZOT-GARCHER 2020-1</org_study_id>
    <nct_id>NCT04819893</nct_id>
  </id_info>
  <brief_title>Study of the Involvement of Fatty Acids in Retinopathy of Prematurity: Relationship Between Retinopathy of Prematurity and the Rate of Expression of Transplacental Fatty Acid Receptors.</brief_title>
  <acronym>OMEGAROP 2</acronym>
  <official_title>Study of the Involvement of Fatty Acids in Retinopathy of Prematurity: Relationship Between Retinopathy of Prematurity and the Rate of Expression of Transplacental Fatty Acid Receptors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The development of the retinal vascular network is completed during the third trimester of&#xD;
      pregnancy and and the first 15 days of life of the newborn. This late maturation can be&#xD;
      problematic in cases of preterm births and result in immature retinal vascularization, known&#xD;
      as retinopathy of prematurity (ROP). Among the various factors influencing retinal vascular&#xD;
      development, the tissue content of omega-3 polyunsaturated fatty acids (PUFAs) appears to be&#xD;
      a crucial element. In a previous project, OMEGA-ROP, we showed a difference in the blood&#xD;
      bioavailability of omega-3 PUFAs in infants born at less than 28 weeks of amenorrhea who&#xD;
      develop ROP compared to healthy newborns with no retinopathy. This study also showed that&#xD;
      mothers experienced variations in the blood levels of omega-3 PUFAs that were contrary to the&#xD;
      types of variations observed in their children. This suggests a sequestration of omega-3&#xD;
      PUFAs in the mothers of children who will develop ROP. This new project aims to better&#xD;
      understand the underlying molecular mechanisms by studying the expression levels of placental&#xD;
      fatty acid receptors in relation to the development of ROP in newborns.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimation of the linear correlation coefficient between placental fatty acid receptor expression rate and term of delivery</measure>
    <time_frame>16 weeks maximum after birth</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prematurity</condition>
  <condition>Retinopathy</condition>
  <arm_group>
    <arm_group_label>Women giving birth prematurely</arm_group_label>
    <description>Delivery before 29 WA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Women giving birth at term</arm_group_label>
    <description>Childbirth between 39WA and 31WA+6 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Maternal blood sampling</intervention_name>
    <description>5 mL sample of venous blood on arrival at the maternity ward in accordance with standard protocols</description>
    <arm_group_label>Women giving birth at term</arm_group_label>
    <arm_group_label>Women giving birth prematurely</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical cord blood sampling</intervention_name>
    <description>0.5mL sample from the umbilical cord after childbirth standard protocols</description>
    <arm_group_label>Women giving birth at term</arm_group_label>
    <arm_group_label>Women giving birth prematurely</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placenta sampling</intervention_name>
    <description>Sampling of 3 cotyledons by cutting across the thickness of the placenta</description>
    <arm_group_label>Women giving birth at term</arm_group_label>
    <arm_group_label>Women giving birth prematurely</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>Newborn, Maternal and Premature Retinopathy Screening Data Collection</description>
    <arm_group_label>Women giving birth prematurely</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women giving birth at term or prematurely&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Mothers giving birth to premature babies less than 29 weeks of amenorrhea (WA), after&#xD;
             obtaining their non-opposition.&#xD;
&#xD;
          2. Mothers giving birth at term between 39 and 41WA+6 days, after obtaining their&#xD;
             non-opposition.&#xD;
&#xD;
          3. ≥18 years&#xD;
&#xD;
          4. Mothers not under legal protection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mothers giving birth between 29WA and 38WA+6 days&#xD;
&#xD;
          2. Mothers in critical condition.&#xD;
&#xD;
          3. Person not affiliated to national health insurance&#xD;
&#xD;
          4. For full-term mothers: patient presenting or having presented a health condition that&#xD;
             affected a previous pregnancy (vascular such as pregnant hypertension, preeclampsia;&#xD;
             gestational diabetes; intrauterine growth retardation, maternal infection during&#xD;
             pregnancy such as toxoplasmosis, cytomegalovirus, rubella, measles, chickenpox).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Catherine CREUZOT-GARCHER</last_name>
    <phone>03.80.29.51.73</phone>
    <email>catherine.creuzot-garcher@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Dijon Bourogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chloé Carré</last_name>
      <email>ccarre34@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

